Announcements Trials
Browse Landscape

Phase

Phase NA 13Phase 1/2 5Phase 2 3Phase 1 3Phase EARLY_PHASE1 2Phase 3 1Phase 2/3 1

Status

Completed 3Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 7Breast 5Thoracic 4Gynecologic 3Sarcoma 2Head & Neck 2Genitourinary 2Dermatologic 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Trastuzumab 72Paclitaxel 63Cyclophosphamide 56pembrolizumab 52Fulvestrant 42Carboplatin 39Capecitabine 37Docetaxel 32Letrozole 27Doxorubicin 23palbociclib 21pertuzumab 20Nivolumab 18eribulin 17abemaciclib 17ribociclib 16Gemcitabine 16130-nm albumin-bound paclitaxel 16durvalumab 15Everolimus 15Albumin-Bound Paclitaxel 15sacituzumab govitecan 14Lapatinib 14Filgrastim 14fludarabine 13exemestane 13Taxes 13Bevacizumab 13Cisplatin 12olaparib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Cryosurgery × Breast × Clear all
NCT05806385 2025-09-09

LOGIC

Texas Tech University Health Sciences Center

Phase 1/2 Not yet recruiting
36 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03183206 2020-07-13

Safety and Efficiency of γδ T Cell Against Breast Cancer

Fuda Cancer Hospital, Guangzhou

Phase 1/2 Completed
100 enrolled
Breast

Breast Neoplasms

NCT01065441 2020-01-22

Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer

Mirror Biologics, Inc.

Phase 1/2 Completed
9 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT02018419 2020-01-22

MBC

Mirror Biologics, Inc.

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

NCT02844335 2019-09-12

Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer

Fuda Cancer Hospital, Guangzhou

Phase 1/2 Completed
60 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡